
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
Over 22,000 attendees and more than 7,400 abstracts, including a record 265 clinical trial abstracts. This section collects on-site analysis across fifteen signal directions, plus late-breaking, clinical-trial and new-drug abstracts.
x.com@Score6060 Heat 2418 likes1 reply5 repostsx.com@Score6060 Heat 65 likes0 replies1 repostx.com@Score6060 Heat 22 likes0 replies0 repostsx.com@Score6060 aacr.orgScore6060 Clinical Trial Results: Intralesional Nivolumab for Precancerous Oral Lesions
Phase I trial led by Moran Amit (MD Anderson): direct nivolumab injection shrank treated lesions by about 60% on average in 25 of 29 patients, spared surgery, and kept 82.13% of lesions cancer-free at 12 months.
Same topic nivolumab · 25 peopleNo engagement yetx.com@Score6060 Heat 1510 likes0 replies5 repostsx.com@Score6060 x.com@Score6060 x.com@Score6060 Mental notes from @AACR #AACR26
x.com@Score6060 Heat 3026 likes1 reply3 repostsx.com@Score6060 Same topic daraxonrasib · 64 peopleKRAS#PANCREATICCANCER#DARAXONRASIB#KRASHeat 195158 likes2 replies35 repostsx.com@Score6060 Heat 44 likes0 replies0 repostsx.com@Score6060 Heat 22 likes0 replies0 repostsx.com@Score6060 Heat 11 like0 replies0 repostsx.com@Score6060 x.com@Score6060 Heat 139 likes0 replies4 repostsx.com@Score6060 x.com@Score6060 x.com@Score6060 x.com@Score6060 Heat 00 likes0 replies0 repostsx.com@Score6060 Heat 22 likes0 replies0 repostsx.com@Score6060 Heat 11 like0 replies0 repostsx.com@Score6060 4 layers to peel to see our CLDN18.2 RASi ADC poster!
x.com@Score6060 Heat 86 likes1 reply1 repostx.com@Score6060 🆕 Next-gen KRAS G12C inhibitor elisrasib induced:
x.com@Score6060 Heat 00 likes0 replies0 repostsx.com@Score6060 x.com@Score6060 x.com@Score6060 Heat 1716 likes0 replies1 repostx.com@Score6060 Heat 1712 likes1 reply4 reposts